GMAB
Genmab A/S
There isn't enough reported data to score GMAB yet.
OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
GMAB Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Strong | |
| Unavailable | |
| Strong |
GMAB's profitability and balance sheet are currently strong. There isn't enough data to rate its revenue and cash flow.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
GMAB PE Valuation
GMAB has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
GMAB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Growth | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for GMAB, but weaker profitability. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over GMAB on the outlook, with more favorable profitability expectations.
GMAB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | $12.16 | +85% |
| Q2 2024 | $6.59 | -12% |
| Q1 2024 | $6.85 | -9.9% |
| Q4 2023 | $6.59 | -14% |
| Q2 2023 | $7.48 | +81% |
| Q1 2023 | $7.60 | +101% |
| Q4 2022 | $7.66 | +95% |
| Q2 2022 | $4.14 | +48% |
OSCR has the stronger earnings trend. Trailing diluted EPS is up 63% for GMAB versus OSCR up 147%.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
GMAB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $2.1B | +17% |
| Q4 2024 | $1.8B | +27% |
| Q2 2024 | $115.8M | -81% |
| Q1 2024 | $89.6M | -79% |
| Q4 2023 | $1.4B | +1.2% |
| Q2 2023 | $619.6M | +32% |
| Q1 2023 | $421.2M | +34% |
| Q4 2022 | $1.4B | +89% |
OSCR has the stronger quarterly revenue trend. Revenue is up 49% for GMAB versus up 72% for OSCR.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | 25% | -11 points |
| Q4 2024 | 36% | +0.4 points |
| Q2 2024 | 30% | +16 points |
| Q1 2024 | 19% | -30 points |
| Q4 2023 | 36% | -3.5 points |
| Q2 2023 | 35% | +11 points |
| Q1 2023 | 15% | -20 points |
| Q4 2022 | 49% | +9.4 points |
GMAB's operating margin was 25% last quarter, down 11 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
GMAB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $822M | +20% |
| Q4 2024 | $685.5M | +30% |
| Q2 2024 | $32M | -37% |
| Q1 2024 | $32M | -93% |
| Q4 2023 | $526.7M | +63% |
| Q2 2023 | $50.4M | -62% |
| Q1 2023 | $465.3M | +491% |
| Q4 2022 | $323.1M | +300% |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with GMAB at up 218%.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
GMAB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.2% | -7.7M shares |
| 1 year | -1.7% | -10.9M shares |
| 3 years | +4.5% | +27.9M shares |
| 5 years | +4.8% | +30M shares |
GMAB has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q4 2024 | — |
| Q2 2024 | $65.1M |
| Q1 2024 | $11.7M |
| Q4 2023 | — |
| Q2 2023 | $5.2M |
| Q1 2023 | $92.4M |
| Q4 2022 | $94.8M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
GMAB Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2019 | -0.4x | Net Cash |
| Q1 2019 | -0.9x | Net Cash |
| Q4 2018 | -0.4x | Net Cash |
| Q3 2018 | -0.6x | Net Cash |
| Q2 2018 | -0.9x | Net Cash |
| Q1 2018 | -0.6x | Net Cash |
| Q4 2017 | -1.0x | Net Cash |
| Q3 2017 | -0.8x | Net Cash |
GMAB has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
GMAB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 75.6 | Overbought |
| Stochastic | 81.0 | Overbought |
GMAB's weekly RSI is 76 (overbought) and its Stochastic is 81 (overbought).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
GMAB PE vs Healthcare Sector
| Metric | GMAB | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
GMAB has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
GMAB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $43.8 | 18% above |
| 20 week MA | $36.3 | 43% above |
| 50 week MA | $31.8 | 63% above |
| 100 week MA | $27.7 | 87% above |
| 200 week MA | $29.7 | 74% above |
GMAB has climbed back above all five of its weekly moving averages, and it's now 74% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
GMAB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $22.3 | $39.1 | +76% |
| 2021 | $39.1 | $39.7 | +1.5% |
| 2022 | $39.7 | $43.1 | +8.5% |
| 2023 | $43.1 | $31.8 | -26% |
| 2024 | $31.8 | $21.0 | -34% |
| 2025 | $21.0 | $33.4 | +59% |
| 2026 YTD | $33.4 | $51.7 | +55% |
GMAB has finished higher in four of the last six years, two of them by more than 50%. It's up 55% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over GMAB on returns for 2026, with the stronger performance.